Nutrition and chronic kidney disease  by Fouque, Denis et al.
Nutrition and chronic kidney disease
Denis Fouque1,2, Solenne Pelletier1,3, Denise Mafra1,4 and Philippe Chauveau5
1Department of Nephrology, Hoˆpital Edouard Herriot, Lyon, France; 2INSERM Research Unit 1060, Universite´ de Lyon, Oullins,
France; 3INSERM Research Unit 831, Universite´ de Lyon, Lyon, France; 4Department of Clinical Nutrition, Federal University Fluminense,
Niteroi, Brazil and 5AURAD Aquitaine, 2 Alle´e Des Demoiselles, Gradignan, France
The incidence of malnutrition disorders in chronic kidney
disease (CKD) appears unchanged over time, whereas
patient-care and dialysis techniques continue to progress.
Despite some evidence for cost-effective treatments, there
are numerous caveats to applying these research findings on
a daily care basis. There is a sustained generation of data
confirming metabolic improvement when patients control
their protein intake, even at early stages of CKD. A recent
protein–energy wasting nomenclature allows a simpler
approach to the diagnosis and causes of malnutrition. During
maintenance dialysis, optimal protein and energy intakes
have been recently challenged, and there is no longer an
indication to control hyperphosphatemia through diet
restriction. Recent measurements of energy expenditure in
dialysis patients confirm very low physical activity, which
affects energy requirements. Finally, inflammation, a
common state during CKD, acts on both nutrient intake and
catabolism, but is not a contraindication to a nutritional
intervention, as patients do respond and improve their
survival as well as do noninflamed patients.
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After the first hemodialysis sessions in the early sixties,1
Dr Scribner rapidly pointed out key questions that emerged
after these first treatments: how to better control blood
pressure, how to manage chronic anemia, and which nutrients
should be recommended to these patients. Fifty years later in
2010, the two first issues have been largely solved. By contrast,
there is still much to do to fight protein–energy wasting as
present epidemiological studies report between 30 and 50% of
patients with signs of malnutrition.2–5 What are the signs or
protein–energy wasting? Are these symptoms already present
before dialysis? Is this possible to correct these abnormalities
and how? In this review, we will try to answer some of these
important points.
CHRONIC KIDNEY DISEASE: WHICH PROTEIN INTAKE BEFORE
MAINTENANCE DIALYSIS?
There is now evidence that patients with chronic kidney
disease (CKD) should control their protein intake to reach
optimal body protective values.6 After an extensive review of
the literature, most of the scientific societies worldwide
recommend a daily allowance of 0.6–0.8 g protein/kg/day for
CKD patients with or without diabetes.7–11 Clinical trials
confirmed by meta-analyses on large numbers (e.g., more
than 2000 patients) show that it is effective and safe to reduce
protein intake from the western-type diet, which contains
about 1.3–1.4 g protein/kg/day to a nutritionally and
metabolically optimal intake of 0.6–0.8 g protein/kg/day.12,13
This is particularly important in patients with proteinuria,
including those with diabetic nephropathy, as any increase in
protein intake will increase proteinuria, which per se, is a risk
factor for CKD progression.14,15 Furthermore, reducing
protein intake decreases proteinuria as efficiently as angio-
tensin-converting enzyme inhibitors,16,17 improves serum
lipid profile,18 and has an additional effect on proteinuria
reduction to that of angiotensin-converting enzyme inhibi-
tors.19 Thus, based solely on proteinuria, there is a strong
rationale to control protein intake.
Limiting protein intake is associated with an instant
decrease in wasted products and uremic toxins, blood urea
nitrogen levels, and acid load. Metabolic consequences of
restricted protein diet have been extensively reviewed:6
reduction in oxidative stress, amelioration of insulin
resistance, better control of metabolic bone disorders in
response to a reduced phosphate load, and subsequent
improvement in anemia control.20–23
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Nutritional safety of a controlled protein intake
As CKD is associated with protein–energy wasting,24 the
nutritional safety of such a protein reduction has been
questioned.25 Muscle wasting is associated with CKD and
increases dependency, mortality, and morbidity in this
population.26 From a basic point of view, one should find a
direct relationship between reduced protein intake and
muscle wasting. Unfortunately, this approach is not clinically
relevant: muscle wasting in chronic diseases is mainly due to
an imbalance between protein synthesis and degradation, and
is further worsened by inactivity.27 In addition, acidosis and
activation of the ubiquitin–proteasome pathway associated
with inflammation and insulin resistance represent the main
factors of muscle wasting.26,28 Reducing protein intake has
been shown to improve all these catabolic conditions. Indeed,
a better control of metabolic acidosis due to a lower acid load
leads to a normalization of the adaptive responses to dietary
protein restriction, as it has been clearly demonstrated in
animals models, CKD, and dialysis patients,29–31 and seems
beneficial on the progression of CKD.31 Insulin resistance is
associated with muscle protein breakdown in end-stage renal
disease patients32 and rapidly improves after 3 months of
low-protein diet (LPD).22 Recent experimental data suggest
that an increase in blood urea nitrogen induces reactive
oxygen species production and enhances insulin resistance.33
Protein intake and oxidative stress
Oxidative stress and upregulation of oxidative metabolism
are among the main factors responsible for sarcopenia in
chronic disease and in aging. Recent data suggest that
oxidative stress is associated with severe disturbances of
muscle function even without muscle atrophy.34 Moreover,
oxidative stress is probably one of the main factors that
aggravate glomerulosclerosis and fibrosis during CKD.
A low-protein intake confers a protection against oxidative
stress in experimental studies.35,36 Finally in CKD patients
treated with LPD or supplemented very low-protein
diet (SVLPD), long-term studies on body composition did
not find any adverse effect of such diets on muscle or lean
body mass.37–39
Quality of protein intake (and not only quantity) should
also be addressed. First, despite debate and controversies,
clinical studies in patients receiving LPD (0.6–0.8 g/kg/day)
or SVLPD (0.3–0.6 g/kg/day, supplemented with amino acids
or keto-analogs) are nutritionally safe. No case of malnutri-
tion occurred, in response to an adequate metabolic
adaptation.13,17 In the Modification of Diet in Renal Disease
study, 9 months after completion of the study, the mean
serum albumin was 42 g/l, and in the 239 patients of the
Bordeaux cohort, only two patients stopped an SVLPD diet
for reason of malnutrition, whereas the mean cohort serum
albumin at start of renal replacement therapy was 39 g/l.40,41
Beneficial effects of a nutritional support
Most patients who start renal replacement therapy without
prior dietary follow-up do present symptoms of malnutrition,
for example, loss of body weight, altered anthropometry, and
laboratory nutritional parameters.42 The occurrence of a
previous nutritional care plan appears to be the main
protective factor against this progressive wasting. First,
nutritional support and patient information are key factors
to ensure motivation and adherence to the diet. This fact has
been clearly demonstrated by Campbell et al.,43 using body
composition analysis and subjective global assessment.
Second, in clinical studies, an LPD is usually composed of
50% protein of high biological value (such as meat, fish, or
egg). In the case of SVLPD, no malnutrition occurred and
long-term survey during or after the start of renal replace-
ment therapy did not show a greater relative risk of death.41
Third, animal experiments and studies in elderly patients
renewed attention on protein quality and the importance of
essential amino acids intake. Indeed, in the elderly, a protein
intake higher than 0.8 g/kg/day is recommended to avoid
sarcopenia due to a relative resistance of muscle to the
anabolic effect of an amino-acid load.44 However, this
resistance could be inhibited using amino-acid mixtures,
particularly those enriched in branched-chain amino acids,
that is, leucine, isoleucine, and valine.45 An indirect evidence
of the effect of amino acids on CKD-associated sarcopenia is
reflected by the observation that, in dialysis patients,
resistance training effect on muscle metabolism is enhanced
when combined with intradialytic parenteral nutrition.46 In
elderly, sarcopenia is partly explained by enhanced oxidative
stress. In nephrectomized rat, increased oxidative stress
caused by protein malnutrition impairs the glomerular
filtration barrier and a supplementation with ketoacids
reduced kidney and oxidative stress injury.35
Finally, clinical studies using LPD or SVLPD bear a great
attention on energy intake. Specific dietary survey is provided
to ensure a sufficient amount of calories, for example,
B35 kcal/kg/day. This is not always the case in most renal
units where time of dietitian is lacking. In conclusion, the
beneficial effects of reducing protein intake to optimal values
are obscured by the lack of physician confidence, dietitian
time, and patient education. Although immediately costly
and sometimes tricky to set up, nutritional support should be
provided for the patient’s sake and is clearly cost-effective
over the long term.47
PROTEIN–ENERGY WASTING: HOW TO MONITOR
NUTRITIONAL RISKS AND IMPROVE OUTCOME?
One of the major side effects of kidney disease is the subtle
development of anorexia and the concurrent reduction of
protein–energy intake, already present at stage III of CKD48
and during dialysis.49–51 A number of orexigenic or
anorexigenic hormone dysregulations (leptin, ghrelin, pep-
tide YY, and obestatin) have been proposed to explain
anorexia in healthy adults and patients.52–54 Administering
recombinant ghrelin during 7 days has been showed to
increase meal energy intake by B25% in malnourished
hemodialysis patients.55 Interestingly, Cheung et al. suggested
a dysfunction of hypothalamic appetite-regulating sensors,
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such as the melanocortin-4 receptor.56,57 Chronic renal
failure mice knockout for this receptor ate normally, whereas
their wild-type melanocortin-4 receptor counterparts se-
verely reduced their food intake as a response to kidney
failure.56 When a melanocortin-4 receptor antagonist (such
as NBI-12i) was administered to uremic mice, they gained
lean and fat mass while lowering their energy expenditure,
resulting in a net nutritional improvement. These findings
may represent an interesting field to explore in order to
improve patients appetite and food intake.
Growth hormone has also been associated with improved
food efficiency in CKD. Indeed, Mehls et al.58 reported that
uremic rats receiving recombinant growth hormone gained
more weight per gram food intake than uremic rats receiving
vehicle. Combining growth hormone and insulin-like growth
factor-1 improved food utilization and anabolic response in
experimental59 and clinical CKD.60
Muscle wasting is a predominant feature of CKD and is
particularly present in long-term maintenance dialysis
patients. Low muscle mass is associated with increased
mortality.61 Muscle wasting results partly from reduced
physical activity (see section below) but also because of
resistance to anabolic factors. The impaired action of growth
hormone and/or insulin-like growth factor-1 has been
studied in detail during maintenance dialysis in children
and adults as well.62–64 Short-term therapeutic interventions
have been successful in improving body composition,65,66
however side effects request long-term studies that are not yet
available. As there is a testosterone deficit, which is associated
with superimposed mortality in men,67 it may be interesting
to test short courses of androgen support in case of severe
cachexia and muscle wasting,68 in association with physical
training. Indeed, most anabolic factors will not be efficient if
they are not associated with a rehabilitation program.
In order to clarify the definition of kidney-associated
protein–energy wasting, the International Society for Renal
Nutrition and Metabolism released in 2008 a nomenclature
paper focused on the causes, consequences, and diagnostic
criteria of impaired nutritional status in CKD patients.24
Four groups of parameters were examined (Table 1): serum
chemistry, body composition, muscle mass, and dietary
intake. For each parameter, a threshold was given based on
the most recent epidemiological studies in CKD patients.
Protein–energy wasting is then identified if at least one
parameter is found below recommendation in three of the
four marker groups,24 and this simple estimation can be
performed at bedside. The next steps are to validate this
classification and identify a protein–energy wasting score that
can predict mortality. A preliminary approach has been
recently reported by de Mutsert et al.69 using the 7-point
subjective global assessment scale, which is a combination of
clinical symptoms of malnutrition and biological abnormal-
ities. In this prospective cohort of 1601 maintenance
hemodialysis patients followed in the NECOSAD-II study,
the increase in 7 years mortality was clearly linked to a point-
by-point decrease in subjective global assessment.69
Table 1 | Criteria for clinical diagnosis of protein–energy wasting (PEW), from Fouque et al.,24 with the permission of Nature
Publishing
Criteria
Serum chemistry
Serum albumin o3.8 g/dl (Bromcresol Green)a
Serum prealbumin (transthyretin) o30mg/dl (for maintenance dialysis patients only; levels may vary according to glomerular filtration rate level
for patients on CKD stages 2–5)a
Serum cholesterol o100mg/dla
Body mass
BMI o23 kg/m2 b
Unintentional weight loss over time: 5% over 3 months or 10% over 6 months
Total body fat percentage o10%
Muscle mass
Muscle wasting: reduced muscle mass 5% over 3 months or 10% over 6 months
Reduced mid-arm muscle circumference areac (reduction 410% in relation to 50th percentile of reference population)
Creatinine appearanced
Dietary intake
Unintentional low-dietary protein intakeo0.80 g/kg/day for at least 2 monthse for dialysis patients oro0.6 g/kg/day for patients on CKD stages 2–5
Unintentional low-dietary energy intake o25 kcal/kg/day for at least 2 monthse
Abbreviation: BMI, body mass index.
At least three out of the four listed categories (and at least one test in each of the selected categories) must be satisfied for the diagnosis of kidney disease–related PEW.
Optimally, each criterion should be documented on at least three occasions, preferably 2–3 weeks apart.
aNot valid if low concentrations are due to abnormally great urinary or gastrointestinal protein losses, to liver disease or to cholesterol-lowering medicines.
bA lower BMI might be desirable for certain Asian populations; weight must be edema-free mass, for example, postdialysis dry weight. See text for the discussion about the
BMI of the healthy population.
cMeasurement must be performed by a trained anthropometrist.
dCreatinine appearance is influenced by both muscle mass and meat intake.
eCan be assessed by dietary diaries and interviews, or for protein intake by calculation of normalized protein equivalent of total nitrogen appearance (normalized protein
nitrogen appearance or normalized protein catabolic rate) as determined by urea kinetic measurements.
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WHAT IS THE OPTIMAL PROTEIN INTAKE IN MAINTENANCE
HEMODIALYSIS?
In the seventies, a number of metabolic studies were performed
in dedicated research wards to better characterize protein and
energy requirements of maintenance dialysis patients. Most of
these studies were by the same teams, including a limited
number of patients due to the time-consuming nature of
research: every time one nutritional parameter is modified
(for example, testing 1.0 g protein/kg/day in six patients), a
new metabolic equilibrium is to be reached only after
2–3 weeks. Thus, testing three different protein intakes
after a baseline period will need at least 2 months of full
hospitalization for each patient with daily collection of blood,
urine, feces, and dialysate output.70–72 These constraints
explain why so few patients were studied and why some
large interindividual needs were identified. As a consequence,
the optimal protein and energy needs were defined above
the minimal requirements observed in the patient who
requested the highest level, whereas some other did well for
slightly lower values (safety principle). From these experi-
mental studies, a protein intake between 1.0 and 1.1 g/day (as
measured by direct food intake) was associated with neutral
nitrogen balance,70–72 and a general agreement was made
upon requirements of 1.2 g/kg/day in maintenance hemo-
dialysis and 1.2–1.3 g/kg/day in peritoneal dialysis. These
values were enforced in 2000 by the Kidney Disease Outcome
Quality Initiative Nutritional guidelines.9 However, after
some months or years, physicians who started to evaluate
their patients’ intakes were uncommonly able to reach these
values and felt these targets were inadequate.
More recent epidemiological research provided slightly
different information. Large prospective reports on thou-
sands of patients showed that survival or body composition
did not impair when nutritional intakes were lower
than recommended.73–75 In a French cohort of more than
3000 maintenance hemodialysis patients followed during
30 months between 2007 and 2009 (ref. 76), mortality was
increased only when normalized protein nitrogen appearance
was lower than 0.7 g protein/kg/day (Figure 1), whereas no
additional mortality was observed for normalized protein
nitrogen appearance values greater than 1.5 g protein/kg/day,
by contrast to Shinaberger’s report.73 Thus, there is little
doubt that low-protein intakes should be avoided in
maintenance hemodialysis, whereas larger intakes do not
clearly impair survival in these patients.
It is interesting to note that body composition will not
further improve when patients eat above 1.0–1.1 g protein/kg/
day. Indeed, in a prospective cross-sectional Japanese study in
129 maintenance hemodialysis patients, lean body mass or
subcutaneous/visceral fat was not improved when patients
had intakes greater than 0.9–1.1 g protein/kg/day.74 In
another study, two different protein intakes were tested in a
crossover design for 40 weeks each (normalized protein
nitrogen appearance of 1.01±0.18 vs 0.9±0.14 g/kg/day).75
Fifty-eight patients were randomized and their energy intake
was 28–30 kcal/kg/day. Actual dietary protein intake was
1.15 g/kg/day and normalized protein nitrogen appearance
1.0 g/kg/day in the high-protein intake period vs 0.94 and
0.90 g/kg/day, respectively, during the low-protein intake
period. There was no change in body weight, lean body mass,
and fat mass in either group, nor was any change in serum
albumin during the different intakes for 40 weeks each, a
sufficient time exposure to reveal wasting. Thus, in this
report, an intake of 0.95 g protein/kg/day or a normalized
protein nitrogen appearance greater than 0.9 appeared
sufficient to maintain adequate body composition and
laboratory values, and there was no greater nutritional
benefit from a higher protein intake.75 With this in mind,
recent guidelines have therefore slightly reduced protein
requirements to 1.1 g/kg/day based on dietary interviews
or 1.0 g/kg/day based on normalized protein nitrogen
appearance.68
WHAT IS THE OPTIMAL PROTEIN INTAKE IN PERITONEAL
DIALYSIS?
Data are more limited and still discussed regarding the
optimal protein intake in peritoneal dialysis patients.
Peritoneal dialysis is associated with albumin and amino-
acid losses in the spent dialysate, which can reach 5–15 g/day,
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Figure 1 |Mortality rate of hemodialysis patients based on
protein intake. Protein intake (g/kg/day) and 30-month hazard
ratio for mortality in a prospective cohort of French hemodialysis
patients from June 2007 to December 2009 (n¼ 3000, adjusted
for age, gender, serum albumin, body mass index, cardiovascular
history, and diabetes; from Fouque et al.,76 with the permission of
the National Kidney Foundation). nPNA, normalized protein
nitrogen appearance.
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seven times per week as compared with hemodialysis losses
that only happens three times weekly.77,78 These losses may
representB15% of the net daily protein intake. Interestingly,
new dialysis regimen, such as automated peritoneal dialysis,
does not appear to modify these losses.78 Anorexia may occur
in response to intraperitoneal glucose load and abdominal
filling, and actual protein intakes of 1.0 g/kg/day or less are
often reported.79 Studies in metabolic ward in rather young
adults have shown in the eighties that a protein intake of
about 1.2 g protein/kg/day was associated with neutral or
positive protein balance in all patients; however, most
patients were already in balance for intakes equal or greater
than 1.0 g protein/kg/day.70,72 Current guidelines therefore
mention that protein intake should be 1.0–1.2 g/kg/day9,80,81
and not below 0.8 g/kg/day in any patient.80 As most patients
will not be able to reach 1.2 g protein/kg/day, an intake of
1.0 g/kg may be acceptable if the patient does not express a
decline in nutritional status.80
INCREASING PROTEIN INTAKE IN DIALYSIS: THE PHOSPHATE
PARADIGM
If there is no clear nutritional advantage to increase protein
intake, is there a metabolic risk to do so? This question arises
as protein is linked to phosphate in a strong and accurate
relationship: 1 g protein brings 13–15mg phosphate, of which
30–70% is absorbed through the intestinal lumen. Thus, a
80 kg-patient eating 90 g protein/day may absorb 600–700mg
phosphate daily, which results in a net balance of
1200–1400mg every other day, an amount that cannot
be eliminated through dialysis as a single regular hemodia-
lysis session can only clear 500–600mg phosphate every
other day and 1-day peritoneal dialysis clears B300mg
phosphate. However, this theoretical calculation is not
fully confirmed by clinical observation. Indeed, in a
randomized controlled trial, Kloppenburg et al.75 tested,
during 40 weeks twice, two different levels of protein intake
(0.94 vs 1.15 g protein/kg/day) that did not result in a
variation of serum phosphate (1.89 vs 1.88mmol/l, respec-
tively, P¼nonsignificant), despite a difference in protein
intake of 20 g and phosphate intake of 250mg/day.75 In a
subsequent report, Shinaberger et al.82 showed that, in more
than 50,000 maintenance hemodialysis patients, serum
phosphate slightly increased from 5.8 to 6.3mg/dl when
patients’ normalized protein nitrogen appearance increase
from 1.0 to 1.4 g/kg/day (Figure 2, top). However and more
importantly when analyzing patients’ survival, the more they
ate protein, the more they survived, until reaching a protein
intake of 1.4 g/kg/day or above (Figure 2, bottom).82 In a post
hoc analysis of the HEMO study, Lynch et al.83 also reported
that the patients who received no prescribed dietary
phosphate restriction had the best survival. In a current
follow-up of more than 3000 maintenance hemodialysis
patients in France, survival at 30 month was best for the
highest protein intakes, without a trend for a J-curve
(Figure 1).76 Taken together, these recent studies indicate
that the optimal protein intake in maintenance hemodialysis,
based on nPNA, should be targeted from 1.0 to 1.4 g/kg/day.
There is no such survival data based on protein intake in
peritoneal dialysis patients.
WILL PROTEIN REQUIREMENTS CHANGE IN THE FUTURE? THE
IMPORTANCE OF DIALYSIS MEMBRANES AND TECHNIQUES
Dialysis membranes and techniques have dramatically
evolved. High-flux membranes tend to clear solutes more
rapidly and efficiently, in an attempt to reduce dialysis time.
Hemofiltration techniques, including hemodiafiltration (pre-
or postdilution) are designed to better remove middle
molecules. However, a number of nutrients such as amino
acids, vitamins, and trace elements may also be lost to a
greater extent with these recent highly efficient techniques,
and limited research is available to date to document this
question.
For example, a polysulfone superflux dialyzer has been
shown to induce an albumin loss of approximately 2.5 g per
session during standard hemodialysis condition. When this
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Figure 2 |The phosphate and protein intake paradigm.
Mortality decreases when protein intake increases up to
1.4 g/kg/day (lower panel), despite a slight increase in serum
phosphate (upper panel; from Shinaberger et al.,82 with the
authorization of the American Society of Nutrition). nPNA,
normalized protein nitrogen appearance.
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filter is used during predilution hemodiafiltration, albumin
loss is about 8 g per session, and during postdilution
hemodiafiltration, albumin loss reaches 25 g per session.84
Such an important albumin loss is hardly compatible with a
balanced protein metabolism and cannot be restored by food
intake. In a previous randomized control trial on high-flux
dialyzer and anemia control,85 74 patients were allocated to
two different membranes, a high-flux polymethyl methacry-
late membrane and a low-flux cellulose one. After a 3-month
follow-up, when looking at nutritional parameters, there was
a significant decrease in serum albumin from 3.88±0.55 to
3.64±0.55 g/dl and in serum creatinine from 10.3±2.0 to
9.4±2.9mg/dl in the high-flux membrane group, whereas
dialysis dose did not change, which could be viewed as
deleterious on a nutritional point of view.85 In another study
comparing predilution hemodiafiltration with a high-flux
polysulfone dialyzer vs standard hemodialysis with a low-flux
membrane, Beerenhout et al.86 observed a gain of 1.4 kg of
muscle mass at 1 year in the hemodialfiltration group vs
1.2 kg in the hemodialysis group (Po0.05), whereas there
was no other nutritional or body composition change. Thus,
data are lacking to predict if these emerging dialysis
techniques will improve or may be at risk for patients’
nutritional status. Further research should be encouraged.
ENERGY NEEDS AND PHYSICAL ACTIVITY: A WORRYING
PATTERN
It is cumbersome to estimate an individual’s energy require-
ments, as energy metabolism depends on many variable factors,
such as age, gender, lean body mass, climate, inflammation,
thyroid and parathyroid function. Obviously, in a balanced
state, energy requirements correspond to energy expenditure,
thus a patient should adapt intakes to his/her expenses. Total
energy expenditure is made up from three separate compo-
nents: resting energy expenditure, thermic effect of meals, and
physical activity energy expenditure.87 The accurate estimation
of total energy expenditure in chronic kidney patients is
essential to allow an adequate provision of nutrients; however,
it is a challenge to collect actual physical activity and resting
energy expenditure in these patients.88–91 There are conflicting
results on resting energy expenditure during dialysis,92 and
there is no data on total energy expenditure because physical
activity is hardly monitored.
We have therefore evaluated total energy expenditure
during a 7-day period using a new device called SenseWear
Armband (Body Media, Pittsburgh, PA), which uses
sensors that continuously record movement, heat flux, and
skin temperature allowing a detailed estimation of the
wearer’s energy expenditure, duration of physical activity,
and number of steps walked.93 We monitored 24 main-
tenance hemodialysis patients and compared their results
to 18 age-matched healthy individuals. Total energy expen-
diture of maintenance hemodialysis patients was lower
(29.5±6.6 kcal/kg/day) when compared with healthy indivi-
duals (31.8±7.0 kcal/kg/day), P¼ 0.02. There was a major
reduction in physical activity between patients (4810±3706
steps/day) and healthy individuals (8712±5287 steps/day),
P¼ 0.008. Total energy expenditure was positively correlated
with the steps number (r¼ 0.84, P¼ 0.001; Figure 3).93
We also evaluated the role of the dialysis session in daily
total energy expenditure and observed that patients spent less
energy (28.4±4.8 kcal/kg/day) and walked less (3629±3198
steps/day) during the dialysis days when compared with
the nondialysis days (30.3±7.8 kcal/kg/day; 5323±4254
steps/day, P¼ 0.01). This decrease in physical activity may
be caused by the lack of motion during the 4-h hemodialysis
procedure, the postdialysis fatigue, and the mandatory
commuting time to reach the dialysis facility back and forth.
As a matter of fact, Majchrzak et al.94 also observed that
physical activity was lower on dialysis days when compared
with nondialysis days, suggesting targets for improving
physical activity, both during hemodialysis and on non-
dialysis days. It is therefore mandatory to implement exercise
in CKD patients, as underlined by Painter and Johansen.95 In
addition, exercise has been shown to increase nutrient
utilization during intradialytic parenteral nutrition.46 Re-
search is also needed in order to achieve the best tolerance
and identify-specific training programs (aerobic and resis-
tance exercise) designed for CKD patients.96
Thus, in maintenance dialysis patients, daily energy
requirements may fluctuate between 30 and 40 kcal/kg/day
based on actual physical activity.68 However, the best patient
outcome will result from an increase in physical activity and a
subsequent augmentation in energy intake, and this is a call
for action.
INFLAMMATION: A DOUBLE-EDGE CATABOLIC AND
ANORECTIC SWORD
Chronic inflammation has been identified in CKD in the
mid-nineties97–99 and was thought to be the primarily cause
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Figure 3 |Daily walking and total energy expenditure. The
relationship between total daily energy expenditure (TEE)
estimated by the SenseWear Armband and patient steps number
(mean of 7-day recording, n¼ 24, r¼ 0.84, P¼ 0.001). Healthy
subjects with moderate activity usually walk more than
8000–10,000 steps per day.
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for low-serum albumin concentrations in these patients.
There is a linear risk between serum C-reactive protein (CrP)
and coronary heart disease, stroke and mortality in the
general population,100 and in a healthy elderly population.101
In maintenance dialysis, Kaysen et al.102 reported a double
dependency of serum albumin, positive one with protein
intake as a source of amino acids mandatory to protein
synthesis, and negative one with serum CrP as a marker of
chronic inflammation. More recent reports have confirmed
the major interdependency between inflammation, cardio-
vascular risk, and malnutrition.103,104 As serum albumin is
a strong predictor for mortality, it is tempting to analyze
the potential impact of inflammation on CKD patients’
survival.24
Low-grade chronic inflammation is present in about
30–65% of maintenance dialysis patients.105 Inflammation
seems to increase with age, and in 2008, maintenance
hemodialysis patients aged over 75 years had a median CrP of
6mg/l, which was significantly greater than those aged under
75 years.106 The CrP threshold used to define inflammation is
unclear, and varies between 5 and 10mg/l among studies. In
many reports, other inflammatory markers such as inter-
leukin-1, -6, or tumor necrosis factor-a have been shown to
be elevated and elicit comparable side effects.107,108 However,
these markers are more difficult to collect and more
expensive to measure, and on a routine basis, it seems
acceptable to use CrP. Thus, whatever the cause,99 inflamma-
tion appears to be a common condition of CKD, and until
now, no dialysis technique or medication has been successful
in correcting or even improving inflammation.
The impact of inflammation on nutritional status is
twofold (Figure 4). Inflammation may induce additional
catabolism in CKD patients, as shown by Avesani et al.90
Indeed, any 1mg/l CrP elevation results in a 30 kcal increase
in daily energy expenditure.90 Besides being catabolic,
inflammation is also responsible for anorexia. Experimental
injection of recombinant interleukin-1 in rats dramatically
reduces spontaneous food intake.109 In maintenance hemo-
dialysis patients, serum CrP is negatively linked with
appetite.49,50 Indeed, Kalantar-Zadeh et al.49 reported
in 331 Californian maintenance hemodialysis patients a
significant inverse relationship between an appetite score and
serum CrP. Visfatin, a new adipocyte-derived factor sensitive
to inflammation,110 may also be involved in anorexia in
CKD.111 Based on an appetite questionnaire in 246 main-
tenance hemodialysis patients in Sweden, a high-serum
visfatin (for example, greater than 40 ng/ml) was associated
with poor appetite and a lower plasma amino-acid profile.
Appetite was also influenced by visfatin genotype.111
Chronic inflammation is linked with more impaired
nutritional status. In a 5-year follow-up of 310 Swedish
patients, mortality was greater in patients with a CrP
410mg/l and a subjective global assessment greater than 2,
indicating a worse nutritional status.112 It is interesting to
note that, depending on the way inflammation will impact on
metabolism, a slow process with muscle and fat loss without
hypoalbuminemia may apply if only food intake is reduced as
a consequence of anorexia, whereas a more rapid wasting and
hypoalbuminemia will occur as a consequence of catabolic
events induced by a more active inflammation112 (Figure 4).
This may partly explain why in a maintenance hemodialysis
population some inflamed patients may have a less severe
wasting state than others.
Is this chronic inflammatory-wasting state an irreversible
situation? First, when survival is analyzed according to
nutritional status (for example, subjective global assessment,
normalized protein nitrogen appearance, or serum albumin)
and CrP, patients with a high CrP and a good nutritional
status always survive better than those with a low CrP and a
more impaired nutritional status, conferring some protection
of a better nutritional state to the deleterious effects of
inflammation.112 Second, fortunately, there seems to exist a
therapeutic response to this inflammatory-induced wasting.
Recent interventional studies have shown anabolic responses
to either oral and/or parenteral nutritional supplements in
hemodialysis patients.113–115 Importantly, these responses
also occurred in patients with CrP above 10mg/l.113–115 In
the FINE study after receiving 1 year of supplemental
nutrition, serum albumin and prealbumin of the malnour-
ished inflamed patients did respond better than in the
noninflamed patients.114 Thus, after a careful check-up
aimed at solving obvious inflammation causes, inflamed
patients presenting with protein–energy wasting should be
aggressively treated with nutritional supplements as well
(Figure 4).
Is nutrition responsible for inflammation? The food
content may possibly be responsible for production or
additional accumulation of inflammatory compounds. Plas-
ma advanced glycosylated end-products have been shown to
increase during advanced CKD and could be increased not
only from endogenous metabolism but also from dietary
sources.116 Indeed, about 10% of ingested advanced glyco-
sylated end-products may be absorbed and B60% of this
absorbed amount will be incorporated in tissues.117 Ingesting
food low in advanced glycosylated end-products content
resulted in a plasma advanced glycosylated end-products
reduction.118 As a follow-up to this observation, does a
Catabolism Anorexia
Add supplemental
nutrients
Inflammation
Maintain
regular nutrients
Body proteins
wasting
Figure 4 | The double impact of inflammation on wasting. The
role of inflammation in chronic kidney disease, responsible for
increased catabolism and anorexia, both actions that may induce
protein–energy wasting and loss of body proteins, which can be
counteracted by nutrients.
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protective diet exist? A potential response may be found in
the Mediterranean diet. This diet is rich in vegetables, fruit,
olive oil, and fish, and poor in red meat. It has been
associated with reduced cardiovascular mortality, increased
longevity, and more recently with decreased dementia.119 A
Mediterranean diet possesses anti-inflammatory properties,
improves lipid profile and reduces oxidant stress. For
example, olive oil has been shown to reduce CrP and
oxidized low-density lipoprotein cholesterol.120,121 Whether
this Mediterranean diet possesses protective properties in
CKD should be further studied. Indeed, in maintenance
dialysis, attention should be focused on potassium intake
that could be slightly increased by these diets rich in fruit and
vegetables.
In summary, it appears that inflammation is not only
catabolic but may also induce protein–energy wasting
from a reduction in appetite.24 Interestingly, by contrast
to a generally admitted opinion, inflammation-induced
protein–energy wasting can be reversed by nutritional
supplements.
CONCLUSION
Fifty years after the first dialysis treatments, nutrition is still a
recurrent issue and many disorders are currently not well
understood. However, there has been progress in nutritional
targets in CKD patients before and during maintenance
treatment. Before dialysis, there is good evidence that a long-
standing nutritional care plan, with a control of protein
intake, is efficient in correcting many metabolic disorders,
including proteinuria, and is cost-effective. During dialysis,
nutritional targets have gained in understanding and
phosphate metabolism does not appear a sufficient issue to
reduce protein intake, as compared with the risk of super-
imposed mortality when patients’ intakes are reduced. New
devices recording physical activity report dramatically
reduced energy expenditure in dialysis patients and call for
sustained physical activity plans as a part of routine
treatment. New classification of nutritional disorders in
CKD patients may help physicians to more easily identify
initial protein–energy wasting. Finally, inflammation, a
common CKD disorder, is responsible for anorexia and
catabolism, but inflamed patients can respond to supple-
mental nutrition as well as noninflamed ones.
DISCLOSURE
All the authors declared no competing interests.
REFERENCES
1. Scribner BJ, Buri R, Caner JE et al. The treatment of chronic uremia by
means of intermittent hemodialysis: a preliminary report. Trans ASAIO
1960; 6: 114–122.
2. Aparicio M, Cano N, Chauveau P et al. Nutritional status of haemodialysis
patients: a French national cooperative study. French Study Group for
Nutrition in Dialysis. Nephrol Dial Transplant 1999; 14: 1679–1686.
3. Kobayashi I, Ishimura E, Kato Y et al. Geriatric Nutritional Risk Index, a
simplified nutritional screening index, is a significant predictor of
mortality in chronic dialysis patients. Nephrol Dial Transplant 2010; 25:
3361–3365.
4. Pifer TB, McCullough KP, Port FK et al. Mortality risk in hemodialysis
patients and changes in nutritional indicators: DOPPS. Kidney Int 2002;
62: 2238–2245.
5. Chauveau P, Combe C, Laville M et al. Factors influencing survival in
hemodialysis patients aged older than 75 years: 2.5-year outcome study.
Am J Kidney Dis 2001; 37: 997–1003.
6. Fouque D, Aparicio M. Eleven reasons to control the protein intake of
patients with chronic kidney disease. Nat Clin Pract Nephrol 2007; 3:
383–392.
7. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice
Recommendations for Diabetes and Chronic Kidney Disease. Am J
Kidney Dis 2007; 49: S12–S154.
8. Toigo G, Aparicio M, Attman PO et al. Expert Working Group report on
nutrition in adult patients with renal insufficiency (part 1 of 2). Clin Nutr
2000; 19: 197–207.
9. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI,
National Kidney Foundation. Am J Kidney Dis 2000; 35: S1–S140.
10. Wright M, Jones C. Clinical Practices Guidelines: nutrition in CKD. UK
Renal Association 2010. www.renal.org/guidelines.
11. ANAES. Moyens the´´rapeutiques pour ralentir la progression de
l’insuffisance re´nale chronique chez l’adulte. ANAES 2004; Paris: http://
www.has-sante.fr/portail/plugins/ModuleXitiKLEE/types/FileDocument/
doXiti.jsp?id=c_268116.
12. Fouque D, Laville M. Low protein diets for chronic kidney disease in non
diabetic adults. Cochrane Database Syst Rev 2009: CD001892.
13. Bernhard J, Beaufrere B, Laville M et al. Adaptive response to a low-
protein diet in predialysis chronic renal failure patients. J Am Soc Nephrol
2001; 12: 1249–1254.
14. Levey AS, Greene T, Beck GJ et al. Dietary protein restriction and the
progression of chronic renal disease: what have all of the results of the
MDRD study shown? Modification of Diet in Renal Disease Study group.
J Am Soc Nephrol 1999; 10: 2426–2439.
15. Brantsma AH, Atthobari J, Bakker SJ et al. What predicts progression and
regression of urinary albumin excretion in the nondiabetic population?
J Am Soc Nephrol 2007; 18: 637–645.
16. Aparicio M, Bouchet JL, Gin H et al. Effect of a low-protein diet on urinary
albumin excretion in uremic patients. Nephron 1988; 50: 288–291.
17. Maroni BJ, Staffeld C, Young VR et al. Mechanisms permitting nephrotic
patients to achieve nitrogen equilibrium with a protein-restricted diet.
J Clin Invest 1997; 99: 2479–2487.
18. Bernard S, Fouque D, Laville M et al. Effects of low-protein diet
supplemented with ketoacids on plasma lipids in adult chronic renal
failure. Miner Electrolyte Metab 1996; 22: 143–146.
19. Gansevoort RT, de Zeeuw D, de Jong PE. Additive antiproteinuric effect
of ACE inhibition and a low-protein diet in human renal disease. Nephrol
Dial Transplant 1995; 10: 497–504.
20. Bellizzi V, Di Iorio BR, De Nicola L et al. Very low protein diet
supplemented with ketoanalogs improves blood pressure control in
chronic kidney disease. Kidney Int 2007; 71: 245–251.
21. Di Iorio BR, Minutolo R, De Nicola L et al. Supplemented very low protein
diet ameliorates responsiveness to erythropoietin in chronic renal
failure. Kidney Int 2003; 64: 1822–1828.
22. Rigalleau V, Blanchetier V, Combe C et al. A low-protein diet improves
insulin sensitivity of endogenous glucose production in predialytic
uremic patients. Am J Clin Nutr 1997; 65: 1512–1516.
23. Combe C, Morel D, de Precigout V et al. Long-term control of
hyperparathyroidism in advanced renal failure by low-phosphorus low-
protein diet supplemented with calcium (without changes in plasma
calcitriol). Nephron 1995; 70: 287–295.
24. Fouque D, Kalantar-Zadeh K, Kopple J et al. A proposed nomenclature
and diagnostic criteria for protein-energy wasting in acute and chronic
kidney disease. Kidney Int 2008; 73: 391–398.
25. Ikizler TA. Dietary protein restriction in CKD: the debate continues. Am J
Kidney Dis 2009; 53: 189–191.
26. Workeneh BT, Mitch WE. Review of muscle wasting associated with
chronic kidney disease. Am J Clin Nutr 2010; 91: 1128S–1132S.
27. Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J
Clin Nutr 2010; 91: 1123S–11127.
28. Kalantar-Zadeh K, Mehrotra R, Fouque D et al. Metabolic acidosis and
malnutrition-inflammation complex syndrome in chronic renal failure.
Semin Dial 2004; 17: 455–465.
29. Mitch WE. Metabolic acidosis stimulates protein metabolism in uremia.
Miner Electrolyte Metab 1996; 22: 62–65.
30. Goodship TH, Mitch WE, Hoerr RA et al. Adaptation to low-protein diets
in renal failure: leucine turnover and nitrogen balance. J Am Soc Nephrol
1990; 1: 66–75.
Kidney International (2011) 80, 348–357 355
D Fouque et al.: Nutrition and CKD min i rev iew
31. de Brito-Ashurst I, Varagunam M, Raftery MJ et al. Bicarbonate
supplementation slows progression of CKD and improves nutritional
status. J Am Soc Nephrol 2009; 20: 2075–2084.
32. Siew ED, Pupim LB, Majchrzak KM et al. Insulin resistance is associated
with skeletal muscle protein breakdown in non-diabetic chronic
hemodialysis patients. Kidney Int 2007; 71: 146–152.
33. D’Apolito M, Du X, Zong H et al. Urea-induced ROS generation causes
insulin resistance in mice with chronic renal failure. J Clin Invest 2010;
120: 203–213.
34. Kuwahara H, Horie T, Ishikawa S et al. Oxidative stress in skeletal muscle
causes severe disturbance of exercise activity without muscle atrophy.
Free Radic Biol Med 2010; 48: 1252–1262.
35. Gao X, Wu J, Dong Z et al. A low-protein diet supplemented with
ketoacids plays a more protective role against oxidative stress of rat
kidney tissue with 5/6 nephrectomy than a low-protein diet alone. Br J
Nutr 2010; 103: 608.
36. Peuchant E, Delmas-Beauvieux MC, Dubourg L et al. Antioxidant effects
of a supplemented very low protein diet in chronic renal failure. Free
Radic Biol Med 1997; 22: 313–320.
37. Chauveau P, Vendrely B, El Haggan W et al. Body composition of
patients on a very low-protein diet: a two-year survey with DEXA. J Ren
Nutr 2003; 13: 282–287.
38. Chauveau P, Combe C, Rigalleau V et al. Restricted protein diet is
associated with decrease in proteinuria: consequences on the
progression of renal failure. J Ren Nutr 2007; 17: 250–257.
39. Vendrely B, Chauveau P, Barthe N et al. Nutrition in hemodialysis
patients previously on a supplemented very low protein diet. Kidney Int
2003; 63: 1491–1498.
40. Menon V, Kopple JD, Wang X et al. Effect of a very low-protein diet on
outcomes: long-term follow-up of the Modification of Diet in Renal
Disease (MDRD) study. Am J Kidney Dis 2009; 53: 208–217.
41. Chauveau P, Couzi L, Vendrely B et al. Long-term outcome on renal
replacement therapy in patients who previously received a keto acid-
supplemented very-low-protein diet. Am J Clin Nutr 2009; 90: 969–974.
42. Kaysen GA, Johansen KL, Cheng SC et al. Trends and outcomes
associated with serum albumin concentration among incident dialysis
patients in the United States. J Ren Nutr 2008; 18: 323–331.
43. Campbell KL, Ash S, Davies PS et al. Randomized controlled trial of
nutritional counseling on body composition and dietary intake in severe
CKD. Am J Kidney Dis 2008; 51: 748–758.
44. Wolfe RR, Miller SL, Miller KB. Optimal protein intake in the elderly.
Clin Nutr 2008; 27: 675–684.
45. Kim JS, Wilson JM, Lee SR. Dietary implications on mechanisms of
sarcopenia: roles of protein, amino acids and antioxidants. J Nutr
Biochem 2010; 21: 1–13.
46. Pupim LB, Flakoll PJ, Levenhagen DK et al. Exercise augments the acute
anabolic effects of intradialytic parenteral nutrition in chronic
hemodialysis patients. Am J Physiol Endocrinol Metab 2004; 286:
E589–E597.
47. Locatelli F, Del Vecchio L. How long can dialysis be postponed by low
protein diet and ACE inhibitors? Nephrol Dial Transplant 1999; 14:
1360–1364.
48. Kopple JD, Greene T, Chumlea WC et al. Relationship between
nutritional status and the glomerular filtration rate: results from the
MDRD study. Kidney Int 2000; 57: 1688–1703.
49. Kalantar-Zadeh K, Block G, McAllister CJ et al. Appetite and
inflammation, nutrition, anemia, and clinical outcome in hemodialysis
patients. Am J Clin Nutr 2004; 80: 299–307.
50. Carrero JJ, Qureshi AR, Axelsson J et al. Comparison of nutritional and
inflammatory markers in dialysis patients with reduced appetite. Am J
Clin Nutr 2007; 85: 695–701.
51. Carrero JJ. Mechanisms of altered regulation of food intake in chronic
kidney disease. J Ren Nutr 2011; 21: 7–11.
52. Korner J, Leibel RL. To eat or not to eat–how the gut talks to the brain.
N Engl J Med 2003; 349: 926–928.
53. Mafra D, Jolivot A, Chauveau P et al. Are ghrelin and leptin involved in
food intake and body mass index in maintenance hemodialysis? J Ren
Nutr 2010; 20: 151–157.
54. Mak RH, Cheung W. Adipokines and gut hormones in end-stage renal
disease. Perit Dial Int 2007; 27(Suppl 2): S298–S302.
55. Ashby DR, Ford HE, Wynne KJ et al. Sustained appetite improvement in
malnourished dialysis patients by daily ghrelin treatment. Kidney Int
2009; 76: 199–206.
56. Cheung W, Yu PX, Little BM et al. Role of leptin and melanocortin
signaling in uremia-associated cachexia. J Clin Invest 2005; 115:
1659–1665.
57. Cheung WW, Kuo HJ, Markison S et al. Peripheral administration of the
melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-
associated cachexia in mice. J Am Soc Nephrol 2007; 18: 2517–2524.
58. Mehls O, Ritz E, Hunziker EB et al. Improvement of growth and food
utilization by human recombinant growth hormone in uremia. Kidney Int
1988; 33: 45–52.
59. Hazel SJ, Gillespie CM, Moore RJ et al. Enhanced body growth in uremic
rats treated with IGF-I and growth hormone in combination. Kidney Int
1994; 46: 58–68.
60. Guebre-Egziabher F, Juillard L, Boirie Y et al. Short-term administration
of a combination of recombinant growth hormone and insulin-like
growth factor-I induces anabolism in maintenance hemodialysis. J Clin
Endocrinol Metab 2009; 94: 2299–2305.
61. Noori N, Kopple JD, Kovesdy CP et al. Mid-arm muscle circumference
and quality of life and survival in maintenance hemodialysis patients.
Clin J Am Soc Nephrol 2010; 5: 2258–2268.
62. Mak RH, Cheung WW, Roberts Jr CT. The growth hormone-insulin-like
growth factor-I axis in chronic kidney disease. Growth Horm IGF Res
2008; 18: 17–25.
63. Fouque D, Peng SC, Kopple JD. Pharmacokinetics of recombinant
human insulin-like growth factor-1 in dialysis patients. Kidney Int 1995;
47: 869–875.
64. Fouque D. Insulin-like growth factor 1 resistance in chronic renal failure.
Miner Electrolyte Metab 1996; 22: 133–137.
65. Feldt-Rasmussen B, Lange M, Sulowicz W et al. Growth hormone
treatment during hemodialysis in a randomized trial improves nutrition,
quality of life, and cardiovascular risk. J Am Soc Nephrol 2007; 18:
2161–2171.
66. Fouque D, Peng SC, Shamir E et al. Recombinant human insulin-like
growth factor-1 induces an anabolic response in malnourished CAPD
patients. Kidney Int 2000; 57: 646–654.
67. Carrero JJ, Qureshi AR, Parini P et al. Low serum testosterone increases
mortality risk among male dialysis patients. J Am Soc Nephrol 2009; 20:
613–620.
68. Fouque D, Vennegoor M, ter Wee P et al. EBPG guideline on nutrition.
Nephrol Dial Transplant 2007; 22(Suppl 2): ii45–ii87.
69. de Mutsert R, Grootendorst DC, Boeschoten EW et al. Subjective global
assessment of nutritional status is strongly associated with mortality in
chronic dialysis patients. Am J Clin Nutr 2009; 89: 787–793.
70. Blumenkrantz MJ, Kopple JD, Moran JK et al. Metabolic balance studies
and dietary protein requirements in patients undergoing continuous
ambulatory peritoneal dialysis. Kidney Int 1982; 21: 849–861.
71. Slomowitz LA, Monteon FJ, Grosvenor M et al. Effect of energy intake on
nutritional status in maintenance hemodialysis patients. Kidney Int 1989;
35: 704–711.
72. Bergstrom J, Furst P, Alvestrand A et al. Protein and energy intake,
nitrogen balance and nitrogen losses in patients treated with
continuous ambulatory peritoneal dialysis. Kidney Int 1993; 44:
1048–1057.
73. Shinaberger CS, Kilpatrick RD, Regidor DL et al. Longitudinal associations
between dietary protein intake and survival in hemodialysis patients.
Am J Kidney Dis 2006; 48: 37–49.
74. Ohkawa S, Kaizu Y, Odamaki M et al. Optimum dietary protein
requirement in nondiabetic maintenance hemodialysis patients. Am J
Kidney Dis 2004; 43: 454–463.
75. Kloppenburg WD, Stegeman CA, Hovinga TK et al. Effect of prescribing a
high protein diet and increasing the dose of dialysis on nutrition in
stable chronic haemodialysis patients: a randomized, controlled trial.
Nephrol Dial Transplant 2004; 19: 1212–1223.
76. Fouque D, Pelletier S, Guebre-Egziabher F. Have recommended protein
and phosphate intake recently changed in maintenance hemodialysis?
J Ren Nutr 2011; 21: 35–38.
77. Blumenkrantz MJ, Gahl GM, Kopple JD et al. Protein losses during
peritoneal dialysis. Kidney Int 1981; 19: 593–602.
78. Westra WM, Kopple JD, Krediet RT et al. Dietary protein requirements
and dialysate protein losses in chronic peritoneal dialysis patients. Perit
Dial Int 2007; 27: 192–195.
79. Paniagua R, Amato D, Vonesh E et al. Effects of increased peritoneal
clearances on mortality rates in peritoneal dialysis: ADEMEX, a
prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:
1307–1320.
80. Dombros N, Dratwa M, Feriani M et al. European best practice guidelines
for peritoneal dialysis. 8 Nutrition in peritoneal dialysis. Nephrol Dial
Transplant 2005; 20(Suppl 9): ix28–ix33.
356 Kidney International (2011) 80, 348–357
min i rev iew D Fouque et al.: Nutrition and CKD
81. Wright M, Jones C. Nutrition in CKD: clinical practice guidelines. UK
Renal Association 2010. http://www.renal.org/Clinical/Guidelines
Section/NutritionInCKD.aspx.
82. Shinaberger CS, Greenland S, Kopple JD et al. Is controlling phosphorus
by decreasing dietary protein intake beneficial or harmful in persons
with chronic kidney disease? Am J Clin Nutr 2008; 88: 1511–1518.
83. Lynch KE, Lynch R, Curhan GC et al. The Association between Prescribed
Dietary Phosphate Restriction and Mortality among Hemodialysis
Patients. Clin J Am Soc Nephrol 2011; 6: 620–629.
84. Krieter DH, Canaud B. High permeability of dialysis membranes:
what is the limit of albumin loss? Nephrol Dial Transplant 2003; 18:
651–654.
85. Locatelli F, Andrulli S, Pecchini F et al. Effect of high-flux dialysis on the
anaemia of haemodialysis patients. Nephrol Dial Transplant 2000; 15:
1399–1409.
86. Beerenhout CH, Luik AJ, Jeuken-Mertens SG et al. Pre-dilution on-line
haemofiltration vs low-flux haemodialysis: a randomized prospective
study. Nephrol Dial Transplant 2005; 20: 1155–1163.
87. Kulstad R, Schoeller DA. The energetics of wasting diseases. Curr Opin
Clin Nutr Metab Care 2007; 10: 488–493.
88. Mafra D, Deleaval P, Teta D et al. New measurements of energy
expenditure and physical activity in chronic kidney disease. J Ren Nutr
2009; 19: 16–19.
89. Cuppari L, de Carvalho AB, Avesani CM et al. Increased resting energy
expenditure in hemodialysis patients with severe hyperparathyroidism.
J Am Soc Nephrol 2004; 15: 2933–2939.
90. Avesani CM, Draibe SA, Kamimura MA et al. Resting energy expenditure
of chronic kidney disease patients: influence of renal function and
subclinical inflammation. Am J Kidney Dis 2004; 44: 1008–1016.
91. O’Sullivan AJ, Lawson JA, Chan M et al. Body composition and energy
metabolism in chronic renal insufficiency. Am J Kidney Dis 2002; 39:
369–375.
92. Ortega O, Rodriguez I, Gallar P et al. Significance of high C-reactive
protein levels in pre-dialysis patients. Nephrol Dial Transplant 2002; 17:
1105–1109.
93. Mafra D, Deleaval P, Teta D et al. Influence of inflammation on total
energy expenditure in hemodialysis patients. J Ren Nutr 2011:
doi:10.1053/j.jren.2010.09.006.
94. Majchrzak KM, Pupim LB, Chen K et al. Physical activity patterns in
chronic hemodialysis patients: comparison of dialysis and nondialysis
days. J Ren Nutr 2005; 15: 217–224.
95. Painter P, Johansen KL. Improving physical functioning: time to be a
part of routine care. Am J Kidney Dis 2006; 48: 167–170.
96. Segura-Orti E, Johansen KL. Exercise in end-stage renal disease. Semin
Dial 2010; 23: 422–430.
97. Kaysen GA, Rathore V, Shearer GC et al. Mechanisms of
hypoalbuminemia in hemodialysis patients. Kidney Int 1995; 48:
510–516.
98. Kaysen GA. Inflammation and oxidative stress in end-stage renal disease.
Adv Nephrol Necker Hosp 2000; 30: 201–214.
99. Himmelfarb J, Stenvinkel P, Ikizler TA et al. The elephant in uremia:
oxidant stress as a unifying concept of cardiovascular disease in uremia.
Kidney Int 2002; 62: 1524–1538.
100. Kaptoge S, Di Angelantonio E, Lowe G et al. C-reactive protein
concentration and risk of coronary heart disease, stroke, and mortality:
an individual participant meta-analysis. Lancet 2010; 375: 132–140.
101. Carriere I, Dupuy AM, Lacroux A et al. Biomarkers of inflammation and
malnutrition associated with early death in healthy elderly people. J Am
Geriatr Soc 2008; 56: 840–846.
102. Kaysen GA, Chertow GM, Adhikarla R et al. Inflammation and dietary
protein intake exert competing effects on serum albumin and creatinine
in hemodialysis patients. Kidney Int 2001; 60: 333–340.
103. de Mutsert R, Grootendorst DC, Axelsson J et al. Excess mortality due to
interaction between protein-energy wasting, inflammation and
cardiovascular disease in chronic dialysis patients. Nephrol Dial
Transplant 2008; 23: 2957–2964.
104. de Mutsert R, Grootendorst DC, Indemans F et al. Association between
serum albumin and mortality in dialysis patients is partly explained by
inflammation, and not by malnutrition. J Ren Nutr 2009; 19: 127–135.
105. Stenvinkel P. Inflammation in end-stage renal failure: could it be
treated? Nephrol Dial Transplant 2002; 17(Suppl 8): 33–38; discussion 40.
106. Pelletier S, Roth H, Bouchet JL et al. Mineral and bone disease pattern in
elderly haemodialysis patients. Nephrol Dial Transplant 2010; 25:
3062–3070.
107. Pecoits-Filho R, Barany P, Lindholm B et al. Interleukin-6 is an
independent predictor of mortality in patients starting dialysis
treatment. Nephrol Dial Transplant 2002; 17: 1684–1688.
108. Axelsson J, Rashid Qureshi A, Suliman ME et al. Truncal fat mass as a
contributor to inflammation in end-stage renal disease. Am J Clin Nutr
2004; 80: 1222–1229.
109. Hellerstein MK, Meydani SN, Meydani M et al. Interleukin-1-induced
anorexia in the rat. Influence of prostaglandins. J Clin Invest 1989; 84:
228–235.
110. Malyszko J, Malyszko JS, Mysliwiec M. Visfatin and endothelial function
in dialyzed patients. Nephrology (Carlton) 2010; 15: 190–196.
111. Carrero JJ, Witasp A, Stenvinkel P et al. Visfatin is increased in chronic
kidney disease patients with poor appetite and correlates negatively
with fasting serum amino acids and triglyceride levels. Nephrol Dial
Transplant 2010; 25: 901–906.
112. Avesani C, Carrero J, Axelsson J et al. Inflammation and wasting in
chronic kidney disease: partners in crime. Kidney Int 2006; 70: S8–S13.
113. Fouque D, McKenzie J, de Mutsert R et al. Use of a renal-specific oral
supplement by haemodialysis patients with low protein intake does not
increase the need for phosphate binders and may prevent a decline in
nutritional status and quality of life. Nephrol Dial Transplant 2008; 23:
2902–2910.
114. Cano NJ, Fouque D, Roth H et al. Intradialytic parenteral nutrition does
not improve survival in malnourished hemodialysis patients: a 2-year
multicenter, prospective, randomized study. J Am Soc Nephrol 2007; 18:
2583–2591.
115. Leon JB, Majerle AD, Soinski JA et al. Can a nutrition intervention
improve albumin levels among hemodialysis patients? A pilot study.
J Ren Nutr 2001; 11: 9–15.
116. Uribarri J, Peppa M, Cai W et al. Dietary glycotoxins correlate with
circulating advanced glycation end product levels in renal failure
patients. Am J Kidney Dis 2003; 42: 532–538.
117. Vlassara H, Cai W, Crandall J et al. Inflammatory mediators are induced
by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc
Natl Acad Sci USA 2002; 99: 15596–15601.
118. Uribarri J, Peppa M, Cai W et al. Restriction of dietary glycotoxins
reduces excessive advanced glycation end products in renal failure
patients. J Am Soc Nephrol 2003; 14: 728–731.
119. Albanese E, Dangour AD, Uauy R et al. Dietary fish and meat intake and
dementia in Latin America, China, and India: a 10/66 Dementia Research
Group population-based study. Am J Clin Nutr 2009; 90: 392–400.
120. Buil-Cosiales P, Irimia P, Berrade N et al. Carotid intima-media thickness
is inversely associated with olive oil consumption. Atherosclerosis 2008;
196: 742–748.
121. Estruch R, Martinez-Gonzalez MA, Corella D et al. Effects of a
Mediterranean-style diet on cardiovascular risk factors: a randomized
trial. Ann Intern Med 2006; 145: 1–11.
Kidney International (2011) 80, 348–357 357
D Fouque et al.: Nutrition and CKD min i rev iew
